Yoda et al. also mentioned that the emergence of secondary resistance mutations could be prevented with upfront treatment using the third‐generation inhibitor lorlatinib.25 The results of an ongoing randomized phase 3 trial comparing lorlatinib to crizotinib as first‐line therapy for advanced ALK‐positive lung cancer (NCT03052608) might partly support this hypothesis. The gene discussed is ALK; the disease is lung cancer.